AMAG Announces Presentation of Ciraparantag Data at the International Society on Thrombosis and Haemostasis

Author's Avatar
Jul 12, 2020
Article's Main Image

Data from two Phase 2 randomized, placebo-controlled, dose-ranging studies using ciraparantag demonstrate efficacy and safety in the reversal of apixaban and rivaroxaban